Study of JS001 in Patients With Advanced Neuroendocrine Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 6, 2017

Primary Completion Date

December 11, 2018

Study Completion Date

May 11, 2019

Conditions
Neuroendocrine Tumors
Interventions
BIOLOGICAL

humanized anti-PD-1 monoclonal antibody

humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.

Trial Locations (1)

100142

Beijing Cancer Hospital, Beijing

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Peking University

OTHER

NCT03167853 - Study of JS001 in Patients With Advanced Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter